Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028 is registered in ClinicalTrials.gov with Sanifit Therapeutics S. A. as lead sponsor.

NCT NCT02966028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02966028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)
Lead sponsor
Sanifit Therapeutics S. A.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
September 30, 2019
Enrollment
274 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

calcifications, vascular, cardiovascular abnormalities, cardiovascular diseases, coronary artery calcification, endstage renal disease, esrd